Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma

The aim of this retrospective study was to evaluate the safety and efficacy of SEAM regimen followed by auto-SCT in lymphoma. We retrospectively reviewed the records of patients with lymphoma who underwent auto-SCT with SEAM conditioning regimen from January 2010 to June 2018 at our centre. In total...

Full description

Saved in:
Bibliographic Details
Published in:Hematology (Luxembourg) 2022-12, Vol.27 (1), p.404-411
Main Authors: Zhang, Lihong, Yang, Haifei, Qian, Chongsheng, Zhou, Jihao, Zhu, Qian, Jiang, Yibin, Liu, Shuo, Chen, Xiaochen, Xu, Ting, Qu, Changju, Li, Caixia, Jin, Zhengming, Chu, Jianhong, Zhang, Xinyou, Wu, Depei, Huang, Haiwen
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
autologous stem cell transplantation
carmustine
Cytarabine - adverse effects
Etoposide - adverse effects
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
lymphoma
Lymphoma - therapy
Melphalan - adverse effects
Retrospective Studies
SEAM
Semustine
Stem Cell Transplantation
Transplantation Conditioning - adverse effects
Transplantation, Autologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this retrospective study was to evaluate the safety and efficacy of SEAM regimen followed by auto-SCT in lymphoma. We retrospectively reviewed the records of patients with lymphoma who underwent auto-SCT with SEAM conditioning regimen from January 2010 to June 2018 at our centre. In total, 97 patients were analysed. The median time to neutrophil engraftment and platelet engraftment was 9.5 days (range, 7-15 days) and 12 days (range, 7-25 days), respectively. Grade 3-4 nausea/vomiting, mucositis and diarrhoea were observed in 21.6%, 36.1%, and 11.3% of patients, respectively. Treatment-related mortality at 100 days occurred in 2 patients (2.1%). After a median follow-up time of 53.9 months, the 3-year incidence of disease relapse or progression was 34%. The estimated progression-free survival and overall survival at 3 years were 62% and 75%, respectively. Compared with previous studies using BEAM as the conditioning regimen, this study shows that the SEAM regimen has a comparable efficacy and safety profile. The SEAM regimen is feasible and might be an ideal alternative to BEAM regimen for lymphoma auto-SCT.
ISSN:1607-8454
1607-8454
DOI:10.1080/16078454.2022.2051864